PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Biotechnology

Healthcare
$1.22 +3.91%

+$0.04 today

Market cap
$65.06M
Beta
1.36
P/E (TTM)
-0.8
EPS (TTM)
-$1.47
52W Low $0.96High $1.88

Volume 0.43M

Average 0.38M

PMVP Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

PMV Pharmaceuticals, Inc.NASDAQ: PMVP

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q1 FY2026 net change in cash of $1.15M fell 89.0% year over year, ahead of the -526.2% change in trailing-twelve-month net change in cash. Sequentially, it fell 30.3% from the prior quarter. Over 3 fiscal years it compounded at -64.4% a year.

Context

  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -89.0% holds above the trailing-twelve-month pace of -526.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.15M-30.3% QoQ
Last fiscal yearDec 2025
-$2.89M-223.2% YoY
LTMMar 2026
-$12.21M-526.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.0%——
1 year-223.2%——
3-year CAGR-64.4%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(2.89M) USD
Year-over-year change
-223.2%

Net Change in Cash vs competitors

How PMVP compares with its peers on the latest reported figures

  • PMVP's LTM Mar 2026 net change in cash of $12.21M is the 4th largest of the 9 companies compared; the peer median is $7.68M.
  • Its year-over-year change of -526.2% is the lowest of 9, against a peer median of +208.0%.
  • Over three fiscal years its annual growth of -64.4% compares with a peer median of -41.8%.
PMVP Competitors Peer median
Net Change in Cash for PMVP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$172.33M +307.6%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026$26.05M -291.6%-14.0%285.1%
VXRTVaxart, Inc.LTM Mar 2026$22.05M +1023.2%—8.6%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$12.21M -526.2%-64.4%—
BMEABiomea Fusion, Inc.LTM Mar 2026$9.2M +108.4%-58.2%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$8.63M +4755.2%-79.0%—
CBUSCibus, Inc.LTM Mar 2026$6.74M +832.4%-25.5%157.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M -135.0%——
ATYRaTyr Pharma, Inc.LTM Mar 2026$504K -118.2%—265.3%
Peer median (excluding PMVP) $7.68M+208.0%-41.8%211.2%

Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.85M)(73.32M)(68.96M)(58.71M)(77.74M)
Depreciation & Amortization1.28M650K1.26M1.14M133K
Deferred Income Tax00000
Stock-Based Compensation5.34M10.2M12.38M8.87M5.92M
Change in Working Capital4.12M(568K)5.43M(1.59M)914K
Accounts Receivables00000
Inventory00000
Accounts Payables191K(389K)235K3.34M(3.42M)
Other Working Capital3.93M(179K)5.19M(4.93M)4.34M
Other Non-Cash Items5.87M9.48M(5.76M)(997K)(2.81M)
Operating Cash Flow(46.57M)(63.76M)(55.66M)(51.28M)(73.58M)
Capital Expenditures(1.35M)(7.98M)(962K)(655K)(29K)
Acquisitions (Net)000251K31K
Purchases of Investments(256.85M)(229.2M)(220.54M)(148.29M)(88.2M)
Sales of Investments114.61M235.82M170.96M202.04M158.37M
Other Investing Activities00000
Investing Cash Flow(143.58M)(1.37M)(50.55M)53.35M70.17M
Debt Repayment00000
Common Stock Issued2.02M958K35.12M313K505K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00456K00
Financing Cash Flow2.02M958K35.58M313K505K
Effect of Forex Changes1034K(35K)7K
Net Change in Cash(188.13M)(64.17M)(70.59M)2.35M(2.89M)
Free Cash Flow(47.92M)(71.74M)(56.62M)(51.94M)(73.61M)

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Intrinsic Alpha fair value

Locked

Current Price

$1.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.